In this episode, we speak with leading paediatric allergist Prof. Helen Brough to explore the key factors behind why some children develop allergies to foods such as peanuts, and what we can do to help prevent them. We also examine the latest developments in managing food allergies and the innovations on the horizon that could transform how we treat them.

The GINA 2025 strategy report introduces a more personalised, age-specific, and proactive approach to asthma care. Key updates include the shift away from SABA monotherapy, expanded use of biomarkers for treatment guidance, and increased emphasis on environmental factors like climate change. The guidelines highlight shared decision-making, routine monitoring, and tailored treatment plans, aiming to reduce exacerbations and improve outcomes across all age groups.

In this Future Leaders interview, Dr Hannah Schiff shares how proteomics is revolutionising tuberculosis diagnostics by identifying new, accessible biomarkers. She reflects on her journey from infectious disease research to respiratory medicine, and how large dataset analysis is revealing deeper insights into TB biology. Dr Schiff also offers practical advice on managing clinical-academic balance and encourages early-career doctors to stay curious and open to research opportunities.

In this Future Leaders interview, Dr Alexander Mathioudakis discusses his pioneering work in precision medicine for airway diseases, with a focus on COPD. He explains how his research is uncovering novel biomarkers, like eosinophil trajectories, to guide treatment decisions and improve outcomes. Dr Mathioudakis also shares insights on balancing innovation with evidence-based practice and offers valuable advice for early-career clinicians pursuing academic careers in respiratory medicine.

As touchRESPIRATORY approaches 10 years of providing education for busy respiratory specialists, we are looking to the future—and it certainly looks bright!

GREAT-2 was a phase II, placebo-controlled trial evaluating gremubamab, a bispecific monoclonal antibody, for chronic Pseudomonas aeruginosa infection in bronchiectasis. As part of our ATS 2025 coverage, Dr Merete Long discusses how this targeted therapy disrupts the vicious cycle of infection and inflammation, trial outcomes including significant bacterial load reduction and improved quality of life, and the broader implications for future treatment strategies.

Explore expert perspectives from ATS 2025 with our exclusive interview series. Discover key advances in respiratory care, including updates on COPD, ILD, ventilation strategies, and emerging therapies. Stay informed with concise, clinically relevant insights tailored for healthcare professionals on touchRESPIRATORY.

In this Q&A, Professors David Price and David Halpin discuss their ATS 2025 abstract on improving COPD outcomes through a digital adherence support package. They explore the MAGNIFY trial's design, including how an EMR-driven algorithm identified high-risk patients and how a pharmacist-led intervention combined with a digital inhaler device significantly reduced treatment failure in a real-world primary care setting.

In this EAACI 2025 interview, Dr Remi Gagnon discusses his presentation on the TT-06 phase III trial. This was the first trial to investigate the SQ tree sublingual immunotherapy (SLIT) tablet in children aged 5–17 with tree pollen-induced allergic rhinitis and/or conjunctivitis.

This interview explores the impact of seasonal allergies on quality of life and the background, design, and findings from the study.